US judge won't block 23andMe bankruptcy sale to co-founder
U.S. District Judge Matthew Schelp in St. Louis, Missouri, during a hearing said he would not pause the $305 million sale while he reviews the state's bid for a declaration that 23andMe cannot sell California customers' genetic data without their consent.
A bankruptcy judge rejected those claims on Monday, and California had appealed that ruling to Schelp, who on Tuesday had briefly paused the sale ahead of Thursday's hearing. 23andMe, which filed for bankruptcy in March, is selling its assets to TTAM Research, a new nonprofit founded by Wojcicki.
Schelp during the hearing said it was reasonable for U.S. Bankruptcy Judge Brian Walsh to conclude that California customers would not be harmed because they can opt to delete their accounts and genetic information.
'A stay pending appeal threatens to derail the TTAM sale altogether, and creditors and shareholders would likely suffer,' the judge said.
Schelp extended the temporary stay until 11:59 p.m. on Friday to give California time to seek a stay from the St. Louis-based 8th U.S. Circuit Court of Appeals.
23andMe, TTAM and the office of California Attorney General Rob Bonta did not immediately respond to requests for comment.
California argues the sale violates the state's Genetic Information Privacy Act, which prohibits the transfer and disclosure of genetic data or biological samples to third parties without express permission for each transfer.
The state had sought to prevent California customers' data from being transferred, a step that 23andMe said would effectively kill the sale. California consumers represent about 1.8 million of the approximately 10 million genetic profiles in 23andMe's inventory, according to court filings.
Walsh, the bankruptcy judge, on Monday overruled California's objections. Other states had also made similar objections to the sale.
On Thursday, Bernard Eskandari of the California Attorney General's office told Schelp that the state would have investigated and brought an enforcement action against a company that sold genetic information without consent outside of bankruptcy. And 23andMe customers cannot now be stripped of those protections, he said.
'Bankruptcy is not a hall pass to evade state law,' he said.
But Jeff Recher, a lawyer for the company, countered that California's genetic privacy law only regulates the transfer of data and not the sale of equity.
'This is not a transfer of genetic information, it's a sale of an ownership interest," he said.
Schelp at the end of the hearing agreed the state law does not apply to sales of ownership and said that California likely lacked standing to challenge the sale.
TTAM has said it would continue to protect customers' genetic data and maintain 23andMe's privacy policies, including customers' right to delete their data.
Wojcicki was 23andMe's CEO before its bankruptcy filing, and her new nonprofit's name is an acronym formed from the first letters of the words 'twenty-three and me.'
TTAM won a bankruptcy auction for 23andMe's assets in June, outbidding a $265 million offer from Regeneron Pharmaceuticals (REGN.O).
23andMe filed for bankruptcy after a drop-off in consumer demand and a 2023 data breach that exposed millions of customers' genetic data.
The case is California v. 23andMe Holding Co., U.S. District Court for the Eastern District of Missouri, No. 25-cv-00999.
For California: Bernard Eskandari and Daniel Nadal of the Office of the Attorney General of California
For 23andMe: Jeff Recher, Chris Hopkins and Paul Basta of Paul, Weiss, Rifkind, Wharton & Garrison
For TTAM: Joe Larkin of Skadden Arps Slate Meagher & Flom
Read more:
Judge briefly pauses 23andMe bankruptcy sale amid California's appeal
California fails to stop 23andMe founder from re-acquiring company
23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm
DNA testing firm 23andMe files for bankruptcy as demand dries up
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
18 minutes ago
- Reuters
Devon Energy misses quarterly profit estimates, signs gas supply deals
Aug 5 (Reuters) - Shale producer Devon Energy (DVN.N), opens new tab on Tuesday narrowly missed Wall Street estimate for second-quarter profit and said it had signed two natural gas supply deals amid growing demand for the fuel. The company will supply 50 million cubic feet per day of natgas to an undisclosed buyer over a 10-year period and will provide 65 mmcfd to CPV Basin Ranch Energy Center for a seven-year term as part of the agreemnts. Devon's deal comes a day after Coterra Energy (CTRA.N), opens new tab agreed to supply 50 mmcfd of natgas to the Permian-based energy center, as U.S. energy producers tap into surging domestic electricity consumption, as well as flourishing exports of the superchilled gas. A more than 20% fall in Brent crude prices hurt Devon's quarterly performance, with its average realized price falling to $62.97 per barrel from $78.95 a year earlier. Oil production rose more than 15% rise and natgas output jumped 22% to 1.39 billion cubic feet per day. Devon plans to boost annual free cash flow by $1 billion by the end of 2026 and cut its current-year capital expenditure forecast by $100 million to between $3.6 billion and $3.8 billion. The company expects current-year oil production to be in the range of 384,000-390,000 bpd, compared with a prior view of 382,000-388,000 bpd. The production outlook along with lower capital spending for 2025 are a sign the company's efforts to optimize portfolio are starting to bear fruit, RBC Capital Markets analyst Scott Hanold said. Oklahoma City-based Devon posted an adjusted profit of 84 cents per share for the second quarter, compared with the analysts' estimate of 85 cents, according to data compiled by LSEG.
The Independent
19 minutes ago
- The Independent
Pfizer CEO says pharmaceutical companies want to work with Trump to make medicine more affordable
Pfizer CEO Albert Bourla announced that major pharmaceutical companies are ready to work with the Trump administration to make medicines more affordable and directly available to consumers. This move comes after Trump demanded that 17 drugmakers expand direct-to-consumer options and lower prices to match those in other industrialized countries, threatening to use 'every tool' if they did not comply. Pfizer and Bristol Myers Squibb have already revealed plans to offer their blood thinner Eliquis at a lower price online, building on Pfizer's existing direct-to-consumer telehealth and prescription services. Other companies, such as Eli Lilly and Novo Nordisk, are also exploring direct access for their obesity drugs, aiming to bypass pharmacy benefit managers. Despite potential sector-specific tariffs on pharmaceutical imports, which could escalate to 250 percent, Pfizer expects to meet its financial forecasts, though experts have refuted Trump's claims of significant drug price reductions.
The Independent
19 minutes ago
- The Independent
US won't seek death penalty for Mexican drug lords Ismael 'El Mayo' Zambada and Rafael Caro Quintero
U.S. prosecutors said Tuesday they won't seek the death penalty in their cases against Mexican cartel kingpin Ismael 'El Mayo' Zambada and Rafael Caro Quintero, the drug lord charged with orchestrating the 1985 killing of a U.S. Drug Enforcement Administration agent. Caro Quintero, 72, and Zambada, 75, have pleaded not guilty to an array of drug trafficking charges. The prosecutions are separate, but they similarly target two of Mexico's most notorious narcos. It is unclear whether taking the death penalty off the table signals any possibility of a plea deal with either or both men. Zambada's lawyer, Frank Perez, said only that the government's decision 'marks an important step toward achieving a fair and just resolution.' Prosecutors said last winter that they were having plea discussions with Zambada's lawyer. Prosecutors wouldn't comment further Tuesday after unveiling their death-penalty decision in brief letters to judges. A request for comment was sent to Caro Quintero's lawyer. The cases are unfolding in the same Brooklyn federal courthouse where infamous Sinaloa cartel co-founder Joaquín 'El Chapo' Guzmán was tried and convicted. The Sinaloa cartel is Mexico's oldest criminal group, with various incarnations dating to the 1970s. It is a drug trafficking power player: A former Mexican cabinet member was convicted of taking bribes to help the cartel. Guzmán and Zambada built it from a regional group into a huge manufacturer and smuggler of cocaine, heroin and other illicit drugs to U.S., authorities say. While Zambada was seen as the cartel's strategist and dealmaker, prosecutors have said he also was enmeshed in its violence, at one point ordering the murder of his own nephew. Zambada avoided capture for years, until he was arrested in Texas last year, after what he has described as a kidnapping in Mexico. One of Guzmán's sons, Joaquin Guzmán Lopez, was arrested with Zambada and has pleaded not guilty in a Chicago federal court. Caro Quintero headed the Guadalajara cartel, parts of which later merged into the Sinaloa organization. The White House has called him 'one of the most evil cartel bosses in the world." Prosecutors say he is responsible for sending tons of heroin, methamphetamine, marijuana and cocaine into the U.S. and had DEA agent Enrique 'Kiki' Camarena abducted, tortured and killed as revenge for a marijuana plantation raid. The killing was dramatized in the Netflix series 'Narcos: Mexico.'
